Prostatype Genomics AB (publ) provided revenue guidance for the third quarter of 2023. The Company also projects that revenue growth will return to positive trend in the Third Quarter.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0416 SEK | +7.22% | +1.96% | -56.21% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.21% | 3.52M | |
-16.55% | 8.43B | |
+40.93% | 3.62B | |
-35.59% | 2.61B | |
-7.71% | 2.48B | |
-7.96% | 2.34B | |
-5.93% | 1.94B | |
-18.96% | 1.56B | |
-38.35% | 1.26B | |
+6.91% | 1.1B |
- Stock Market
- Equities
- PROGEN Stock
- News Prostatype Genomics AB
- Prostatype Genomics AB Provides Revenue Guidance for the Third Quarter of 2023